gamma-aminobutyric acid has been researched along with Renal Insufficiency, Chronic in 10 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin relieved itching in 47 patients (66%)." | 9.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "Gabapentin or pregabalin relieved itching in 85% of 71 consecutively treated CKD patients." | 9.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD." | 7.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 7.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "The average pretreatment pruritus score was 9." | 6.78 | Use of pregabalin in the management of chronic uremic pruritus. ( Grenader, T; Lifschitz, M; Shavit, L; Slotki, I, 2013) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 5.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| " We compared dosing and side effects in 34 CKD/ESKD patients with similar patients receiving HD (n = 15)." | 5.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Pruritus and restless legs syndrome (RLS) frequently affect patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), impacting the quality of life." | 5.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Gabapentin relieved itching in 47 patients (66%)." | 5.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "Gabapentin or pregabalin relieved itching in 85% of 71 consecutively treated CKD patients." | 5.16 | Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012) |
| "Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak." | 4.95 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD." | 3.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 3.81 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "The average pretreatment pruritus score was 9." | 2.78 | Use of pregabalin in the management of chronic uremic pruritus. ( Grenader, T; Lifschitz, M; Shavit, L; Slotki, I, 2013) |
| "Any intervention for the treatment of uremic pruritus was included." | 2.55 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients." | 2.55 | Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017) |
| "Gabapentin is a viable treatment for conservatively managed CKD and ESKD patients with pruritus and/or RLS, but side effects are common." | 1.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| " We compared dosing and side effects in 34 CKD/ESKD patients with similar patients receiving HD (n = 15)." | 1.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Pruritus and restless legs syndrome (RLS) frequently affect patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), impacting the quality of life." | 1.42 | Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015) |
| "Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats." | 1.40 | Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats. ( Ayajiki, K; Funai, A; Kobuchi, S; Matsumura, Y; Ohkita, M; Suzuki, R; Tanaka, R; Tsutsui, H; Yazawa, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalantari, S | 1 |
| Chashmniam, S | 1 |
| Nafar, M | 1 |
| Samavat, S | 1 |
| Rezaie, D | 1 |
| Dalili, N | 1 |
| Simonsen, E | 1 |
| Komenda, P | 1 |
| Lerner, B | 1 |
| Askin, N | 1 |
| Bohm, C | 1 |
| Shaw, J | 1 |
| Tangri, N | 1 |
| Rigatto, C | 1 |
| Rayner, H | 1 |
| Baharani, J | 1 |
| Smith, S | 1 |
| Suresh, V | 1 |
| Dasgupta, I | 1 |
| Kobuchi, S | 1 |
| Tanaka, R | 1 |
| Funai, A | 1 |
| Suzuki, R | 1 |
| Yazawa, M | 1 |
| Tsutsui, H | 1 |
| Ohkita, M | 1 |
| Ayajiki, K | 1 |
| Matsumura, Y | 1 |
| Mettang, T | 1 |
| Kremer, AE | 1 |
| Cheikh Hassan, HI | 1 |
| Brennan, F | 1 |
| Collett, G | 1 |
| Josland, EA | 1 |
| Brown, MA | 1 |
| Gargiulo, R | 1 |
| Suhail, F | 1 |
| Lerma, EV | 1 |
| Kitajima, S | 1 |
| Iwata, Y | 1 |
| Furuichi, K | 1 |
| Sagara, A | 1 |
| Shinozaki, Y | 1 |
| Toyama, T | 1 |
| Sakai, N | 1 |
| Shimizu, M | 1 |
| Sakurai, T | 1 |
| Kaneko, S | 1 |
| Wada, T | 1 |
| Gopaluni, S | 1 |
| Sherif, M | 1 |
| Ahmadouk, NA | 1 |
| Shavit, L | 1 |
| Grenader, T | 1 |
| Lifschitz, M | 1 |
| Slotki, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Prospective Randomized Study Evaluating the Efficacy of the Spherical Absorptive Carbon AST-120 in Hemodialysis Patients With Uremic Pruritus..[NCT04639674] | Phase 4 | 100 participants (Actual) | Interventional | 2020-07-02 | Completed | ||
| Identifying a Cardiorenal Protective Diet in a Lower-income African American Population With Chronic Kidney Disease at Risk for Cardiovascular Disease.[NCT04117204] | 101 participants (Actual) | Interventional | 2019-06-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for gamma-aminobutyric acid and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Treatment of Uremic Pruritus: A Systematic Review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom | 2017 |
Uremic pruritus.
Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxyl | 2015 |
Cardiovascular disease and chronic kidney disease.
Topics: Cardiovascular Diseases; Coronary Artery Disease; gamma-Aminobutyric Acid; Heart Diseases; Humans; P | 2015 |
Interventions for chronic kidney disease-associated restless legs syndrome.
Topics: Amines; Anticonvulsants; Ascorbic Acid; Cyclohexanecarboxylic Acids; Dopamine Agonists; Exercise The | 2016 |
2 trials available for gamma-aminobutyric acid and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Uraemic pruritus: relief of itching by gabapentin and pregabalin.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Comorbidity; Cyclohexanecarboxylic Acids; Dose-R | 2012 |
Use of pregabalin in the management of chronic uremic pruritus.
Topics: Aged; Analgesics; Anticonvulsants; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Male; P | 2013 |
4 other studies available for gamma-aminobutyric acid and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Biomarkers; Cholesterol Esters; Cross-Sectional Studies | 2020 |
Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Autonom | 2014 |
Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma- | 2015 |
Messenger RNA expression profile of sleep-related genes in peripheral blood cells in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; gamma-Aminobutyric Acid; Gene Expression Prof | 2016 |